Published in Clin Epigenetics on February 12, 2016
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
The language of covalent histone modifications. Nature (2000) 44.92
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Epigenetics in cancer. N Engl J Med (2008) 17.36
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
An operational definition of epigenetics. Genes Dev (2009) 4.26
PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell (2012) 3.28
Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat Genet (2013) 2.41
Altered cellular proliferation and mesoderm patterning in Polycomb-M33-deficient mice. Development (1997) 2.00
Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol (2013) 1.97
Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol (2014) 1.93
Recognition and specificity determinants of the human cbx chromodomains. J Biol Chem (2010) 1.76
Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle (2006) 1.69
Ovaries and female phenotype in a girl with 46,XY karyotype and mutations in the CBX2 gene. Am J Hum Genet (2009) 1.63
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer (2011) 1.59
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2013) 1.58
Cbx2 targets PRC1 to constitutive heterochromatin in mouse zygotes in a parent-of-origin-dependent manner. Mol Cell (2015) 1.51
Male-to-female sex reversal in M33 mutant mice. Nature (1998) 1.35
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res (2008) 1.29
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl (2014) 1.23
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat Cell Biol (2013) 1.16
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate (2004) 1.14
Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol (2011) 1.09
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer (2011) 1.08
Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett (2006) 1.06
Mouse Polycomb M33 is required for splenic vascular and adrenal gland formation through regulating Ad4BP/SF1 expression. Blood (2005) 1.02
Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice. Oncogene (2004) 0.96
Novel motifs distinguish multiple homologues of Polycomb in vertebrates: expansion and diversification of the epigenetic toolkit. BMC Genomics (2009) 0.95
Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin Epigenetics (2015) 0.86
Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. Br J Cancer (2014) 0.84
Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes. Mol Biol Cell (2014) 0.80